Key result
Dipyridamole reduced plasma vWf levels in both healthy volunteers and stroke patients, demonstrating non-platelet-related effects of antiplatelet agents.
Why the study?
Do aspirin, clopidogrel, and dipyridamole, alone or in combination, improve soluble markers of vascular function in healthy volunteers and patients with prior ischemic stroke?
RCT (n=22)
Blinded
Random order
Do aspirin, clopidogrel, and dipyridamole, alone or in combination, improve soluble markers of vascular function in healthy volunteers and patients with prior ischemic stroke?
Answers are grounded in this paper and cite their sources.
May support non-platelet effects of dipyridamole on vWf; hypothesis-generating and should not yet change practice.
Although the mechanisms of action by which aspirin, clopidogrel and dipyridamole inhibit platelets are well characterised, their effects on soluble modulators of thrombosis, inflammation, and endothelial function have yet to assessed systematically. In this investigation aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in combination (A, C, D, AC, AD, CD, ACD) in random order for 2 weeks (without washout) to 11 healthy subjects and 11 patients with previous ischaemic stroke. At the end of each treatment period plasma cyclic guanosine monophosphate (cGMP), monocyte chemoattractant pertide-1 (MCP-1), nitric oxide metabolites (NO(x)), plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWf); and serum C-reactive protein (CRP) and platelet derived growth factor (PDGF); were measured blinded to treatment. Dipyridamole reduced plasma vWf levels (%) in both volunteers, -10.0 (4.95), and patients, -10.11 (4.34) (p < 0.05). Dipyridamole also lowered CRP (mg/l) in patients, -0.96 (0.47), but not volunteers. Clopidogrel reduced PAI-1 (ng/ml) in volunteers, -5.30 (2.20) (p < 0.05), and patients, -3.61 (2.75) (non-significant trend). Aspirin lowered PDGF (ng/ml) in volunteers, -3.46 (1.55), but not patients. Triple antiplatelet therapy was superior to dual and mono therapy in reducing vWf levels. In conclusion, antiplatelet agents have non-platelet-related effects on soluble modulators of thrombosis, inflammation, and endothelial function. In particular, dipyridamole reduces plasma vWf and clopidogrel lowers plasma PAI-1 levels. These effects may explain, in part, their roles in preventing atherothrombogenesis.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2006) conducted an RCT in Previous ischaemic stroke and healthy volunteers (n=22). Aspirin, clopidogrel, and dipyridamole (singly and in combination) vs. Mono, dual, and triple therapy compared to each other was evaluated on Plasma von Willebrand factor (vWf) levels (p=< 0.05). Dipyridamole reduced plasma vWf levels in both healthy volunteers and stroke patients, demonstrating non-platelet-related effects of antiplatelet agents.
Synapse has enriched 10 related papers. Consider them for comparative context: